The Court of Appeal for England and Wales has ruled that clinical commissioning groups (CCGs) can offer Roche’s Avastin (bevacizumab) to patients with wet age-related macular degeneration, even though it is not licensed for that indication.
In doing so the court has finally put an end to a long-running effort by Novartis and Bayer to prevent...